Study's lead investigator makes a case that the novel stents really are comparable to Xience, Promus
Two ultra-low-profile drug-eluting stents (DES) fell short of demonstrating the prespecified noninferiority criteria in comparison with more-established, commercially approved DES, even though “the totality of the evidence” shows that these new stents are, in fact, noninferior, according to the study’s lead investigator.